Stocks
REGENXBIO Financial Statements (RGNX) |
||||||||||
| REGENXBIOsmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 03.05.2023 | 02.08.2023 | 08.11.2023 | 27.02.2024 | 08.05.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 19.1 | 20.0 | 28.9 | 22.2 | 15.6 | 86.7 | |||
| Operating Income, bln rub | -66.2 | -73.1 | -65.0 | -63.9 | -61.8 | -263.7 | ||||
| EBITDA, bln rub | ? | -66.1 | -68.6 | -64.9 | -59.6 | -57.6 | -250.7 | |||
| Net profit, bln rub | ? | -70.0 | -72.1 | -61.9 | -62.9 | -63.3 | -260.1 | |||
| OCF, bln rub | ? | -80.9 | -47.3 | -49.4 | -40.8 | -55.5 | -192.9 | |||
| CAPEX, bln rub | ? | 4.82 | 2.58 | 1.44 | 1.13 | 0.557 | 5.70 | |||
| FCF, bln rub | ? | -85.7 | -49.9 | -50.8 | -41.9 | -56.0 | -198.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 81.2 | 83.6 | 81.5 | 70.5 | 68.9 | 304.6 | ||||
| Cost of production, bln rub | 4.11 | 9.48 | 12.4 | 15.6 | 8.46 | 45.9 | ||||
| R&D, bln rub | 58.5 | 59.9 | 58.2 | 51.3 | 50.7 | 220.1 | ||||
| Interest expenses, bln rub | 2.76 | 1.12 | 1.62 | 1.36 | 1.97 | 6.08 | ||||
| Assets, bln rub | 747.8 | 682.5 | 633.8 | 574.0 | 629.2 | 629.2 | ||||
| Net Assets, bln rub | ? | 465.1 | 405.9 | 363.1 | 311.7 | 390.7 | 390.7 | |||
| Debt, bln rub | 93.3 | 91.6 | 90.7 | 89.3 | 170.6 | 170.6 | ||||
| Cash, bln rub | 331.8 | 320.1 | 301.9 | 275.3 | 338.7 | 338.7 | ||||
| Net debt, bln rub | -238.5 | -228.5 | -211.2 | -186.0 | -168.1 | -168.1 | ||||
| Ordinary share price, rub | 18.9 | 20.0 | 16.5 | 18.0 | 21.1 | 14.2 | ||||
| Number of ordinary shares, mln | 43.5 | 43.5 | 43.9 | 44.0 | 45.7 | 45.7 | ||||
| Market cap, bln rub | 822 | 870 | 723 | 790 | 964 | 648 | ||||
| EV, bln rub | ? | 583 | 642 | 512 | 604 | 795 | 480 | |||
| Book value, bln rub | 465 | 406 | 363 | 312 | 391 | 391 | ||||
| EPS, rub | ? | -1.61 | -1.66 | -1.41 | -1.43 | -1.38 | -5.69 | |||
| FCF/share, rub | -1.97 | -1.15 | -1.16 | -0.95 | -1.22 | -4.34 | ||||
| BV/share, rub | 10.7 | 9.32 | 8.26 | 7.08 | 8.54 | 8.54 | ||||
| EBITDA margin, % | ? | -345.3% | -343.6% | -224.5% | -268.2% | -368.6% | -289.1% | |||
| Net margin, % | ? | -365.5% | -360.7% | -214.0% | -283.1% | -405.4% | -300.0% | |||
| FCF yield, % | ? | -31.3% | -27.1% | -32.0% | -28.9% | -20.6% | -30.6% | |||
| ROE, % | ? | -61.0% | -69.5% | -72.7% | -85.6% | -66.6% | -66.6% | |||
| ROA, % | ? | -37.9% | -41.3% | -41.6% | -46.5% | -41.3% | -41.3% | |||
| P/E | ? | -2.90 | -3.09 | -2.74 | -2.96 | -3.70 | -2.49 | |||
| P/FCF | -3.20 | -3.69 | -3.13 | -3.46 | -4.85 | -3.26 | ||||
| P/S | ? | 7.49 | 8.97 | 7.28 | 8.75 | 11.1 | 7.48 | |||
| P/BV | ? | 1.77 | 2.14 | 1.99 | 2.53 | 2.47 | 1.66 | |||
| EV/EBITDA | ? | -2.32 | -2.47 | -1.99 | -2.33 | -3.17 | -1.92 | |||
| Debt/EBITDA | 0.95 | 0.88 | 0.82 | 0.72 | 0.67 | 0.67 | ||||
| R&D/CAPEX, % | 1 215% | 2 324% | 4 043% | 4 560% | 9 096% | 3 862% | ||||
| CAPEX/Revenue, % | 25.2% | 12.9% | 4.98% | 5.07% | 3.57% | 6.57% | ||||
| REGENXBIO shareholders | ||||||||||
